BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marcellusi A, Viti R, Kondili LA, Rosato S, Vella S, Mennini FS; PITER Collaborating group available at www.progettopiter.it. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. Pharmacoeconomics 2019;37:255-66. [PMID: 30378086 DOI: 10.1007/s40273-018-0733-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Marcellusi A, Mennini FS, Ruf M, Galli C, Aghemo A, Brunetto MR, Babudieri S, Craxi A, Andreoni M, Kondili LA. Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation. Liver Int 2021. [PMID: 34582627 DOI: 10.1111/liv.15070] [Reference Citation Analysis]
2 Kondili LA, Aghemo A, Andreoni M, Galli M, Rossi A, Babudieri S, Nava F, Leonardi C, Mennini FS, Gardini I, Russo FP. Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. Dig Liver Dis 2021:S1590-8658(21)00142-0. [PMID: 33926816 DOI: 10.1016/j.dld.2021.03.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
3 Marcellusi A, Simonelli C, Mennini FS, Kondili LA; PITER Collaborating Group available at http://www.progettopiter.it. Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis. Appl Health Econ Health Policy 2021. [PMID: 34636024 DOI: 10.1007/s40258-021-00677-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kondili LA, Marcellusi A, Ryder S, Craxì A. Will the COVID-19 pandemic affect HCV disease burden? Dig Liver Dis 2020;52:947-9. [PMID: 32527655 DOI: 10.1016/j.dld.2020.05.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
5 Zappulo E, Scotto R, Buonomo AR, Maraolo AE, Pinchera B, Gentile I. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. Expert Opin Pharmacother 2020;21:261-73. [PMID: 31914336 DOI: 10.1080/14656566.2019.1697674] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
7 Kondili LA, Gamkrelidze I, Blach S, Marcellusi A, Galli M, Petta S, Puoti M, Vella S, Razavi H, Craxi A, Mennini FS; PITER collaborating group. Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver Int 2020;40:1545-55. [PMID: 32078234 DOI: 10.1111/liv.14408] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
8 Mennini FS, Marcellusi A, Robbins Scott S, Montilla S, Craxi A, Buti M, Gheorghe L, Ryder S, Kondili LA. The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries. Liver Int 2021;41:934-48. [PMID: 33529499 DOI: 10.1111/liv.14808] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]